Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FLT3 exon 14 ins |
| Therapy | Ningetinib |
| Indication/Tumor Type | acute myeloid leukemia |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 exon 14 ins | acute myeloid leukemia | sensitive | Ningetinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Ningetinib (CT053PTSA) induced cell cycle arrest and apoptosis and inhibited Flt3 downstream signaling and viability in acute myeloid leukemia cell lines harboring a FLT3-ITD, inhibited Flt3 downstream signaling and proliferation in patient-derived cells in culture, and decreased leukemic burden in a cell line xenograft model (PMID: 38978049). | 38978049 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38978049) | Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia. | Full reference... |